The Whole World is Watching:
MAPS Email Newsletter
December 7, 2012
| Dear MAPS Members and Friends,
It’s been a busy month for psychedelic and medical marijuana research. Most of it is captured in the headlines below—scroll down to see the impressive list of headlines generated by last month’s publication of the results of our landmark long-term follow-up study of MDMA-assisted psychotherapy for PTSD.
From The New York Times and CNN to NBC and Military.com, psychedelic research is in the spotlight. The whole world is watching, and we have a responsibility and a commitment to see our work through.
In a message to our supporters sent by MAPS Executive Director Rick Doblin, Ph.D., last week, we incorrectly stated that Nature had referred to our results as “incredible.” The popular science magazine actually referred to our results as “spectacular” rather than incredible. We apologize for any confusion that might have caused.
Our petition calling on U.S. military officials to support our research into MDMA-assisted psychotherapy for veterans with PTSD already has more than 1,500 signatures. Help us give veterans hope—tell the Pentagon to support our work.
Here are just a few highlights from what else is new:
Early Bird rates for Psychedelic Science 2013 are only available until December 21. Time is running out to save $75 or more on conference registration—you’re not going to want to miss this extraordinary five-day event.
Do you have research of your own that you’d like to present? The submission deadline for papers and posters is January 4—download our Call for Papers for details.
Don’t forget to subscribe to our updates on Facebook, Twitter, and Google+, and visit our YouTube channel for videos about everything from LSD and medical marijuana to psychedelic harm reduction. There really is something for everyone.
The astonishing (or is it spectacular?) transformations we are seeing in science, medicine, the popular press, and our world at large are the direct result of—you guessed it—your support. Will you help us keep up the momentum by making a gift today?
TREATING PTSD WITH MDMA-ASSISTED PSYCHOTHERAPY
Learn more about treating PTSD with MDMA-assisted psychotherapy on or at mdmaptsd.org.
View the all-new infographic that explains our research
into treating PTSD with MDMA-assisted psychotherapy.
On November 20, 2012, the Journal of Psychopharmacology published online the outstanding results of our long-term follow-up of subjects who participated in our initial proof of principle study of MDMA-assisted psychotherapy for PTSD. The long-term follow-up, conducted an average of 45 months (over 3.5 years) after MDMA-assisted psychotherapy, extends the promising results of the initial study (published in 2010) which found that 83% of those receiving MDMA-assisted psychotherapy no longer qualified for a PTSD diagnosis two months after treatment. The long-term follow-up showed that these remarkable benefits were, on average, sustained over time. However, several subjects did relapse and experienced a return of symptoms. Learn more…
On November 8, 2012, after five inspections and over 15 months of resulting delays, an inspector from Health Canada finally approved the security measures at the Vancouver pharmacy where the MDMA will be stored for our upcoming Canadian study of MDMA-assisted psychotherapy for PTSD. New security regulations created after the initial inspection required us to make numerous expensive changes to the pharmacy, including hiding the safe with a wooden cabinet, moving the safe and cabinet to a new room with a solid (rather than glass) door, installing multiple new alarm systems, adding bulletproof polycarbonate over the windows, and placing additional warning labels on the study drug. Learn more…
The treatment room for our upcoming
Israeli study of MDMA-assisted psychotherapy for PTSD
On November 25, 2012, the site team for our new Israeli study of MDMA-assisted psychotherapy for PTSD began collecting inquiries for participation in the study, beginning the screening process. In-person screening will begin on December 12, when our insurance policy goes into effect (which cost us about $8,000). This study will investigate the safety and effectiveness of MDMA-assisted psychotherapy in 10 people with chronic, treatment-resistant PTSD. While the sample size is small, the study will help us to develop our therapeutic approach, evaluate the effectiveness of the double blind, to compare the effectiveness of full (125 mg) versus active placebo (25 mg) doses of MDMA combined with psychotherapy, and to plan the design for future Phase 3 studies. View the timeline…
From December 3-8, 2012, another Israeli co-therapist enrolled in our therapist training protocol in Charleston, South Carolina, as part of training for treating subjects in our upcoming Israeli study of MDMA-assisted psychotherapy for PTSD. The protocol was designed as a Phase 1 study of the psychological effects of MDMA in healthy volunteers, with subjects limited to people in training to work on a MAPS-sponsored study. Learn More…
Looking for more ways to get involved? Check out our Student Resources page!
IBOGAINE TREATMENT FOR ADDICTION
On November 9, 2012, the fifth participant was enrolled in our ongoing observational study of ibogaine treatment for addiction in New Zealand. All participants had been receiving methadone treatment for opiate addiction and are being treated for methadone dependence at independent ibogaine clinics in New Zealand. The study was approved by the IRB on February 22, 2012, and lead investigator Dr. Geoff Noller, Ph.D., began enrollment shortly thereafter. This study is the second in our international series of observational studies of the safety and long-term effectiveness of ibogaine treatment for addiction, building on our completed study in Mexico. Learn More…
Download the all-new
Winter 2012 MAPS Bulletin,
containing our 2012 Annual Report.
In November, 195 individuals donated to MAPS for a total of $11,218 in gifts ranging from $5 to $3,000. In response to the last few weeks of media coverage and an email message from MAPS Founder Rick Doblin, new contributions continue coming in. It is encouraging to see such support for psychedelic research and education. Those individuals contributing their time and money to MAPS share a deep belief that our work is making an important change in the world. Thank you for your generosity. This month we also want to thank The David Rockefeller Fund for a $15,000 gift for our soon-to-start study in Boulder, Colorado, evaluating MDMA-assisted psychotherapy in subjects with chronic, treatment-resistant PTSD. The Mental Insight Foundation has awarded MAPS $50,000 for our study of MDMA-assisted psychotherapy in veterans suffering from PTSD.
Help us make psychedelics and marijuana into prescription medicines—donate today!
Exhibitor spaces for Psychedelic Science 2013 are limited, and spaces are filling up quick, so reserve yours soon. The Marketplace at Psychedelic Science 2013 is a prime opportunity to connect with attendees with an interest in science, health, art, and spirituality and share information about your organization, company, or product. See our Sponsorship Brochure for full details, or contact Brian Brown at firstname.lastname@example.org.
We would like to give a special thanks to our Psychedelic Science 2013 Promotional Partners whose support allows us to conduct our world-changing research and education projects.
Early Bird rates for Psychedelic Science 2013 end on December 21, 2012. Save $75 or more and demonstrate your belief in the future—of psychedelic medicine. The three-day conference (April 19-21) features talks ranging from psilocybin’s effect on mystical experiences (Roland Griffiths, Ph.D.), to how findings from psychedelic psychotherapy research have helped transform psychology (Dr. Stanislav Grof) and much more. Speakers from South America, North America, and Europe will present the latest research on psilocybin for cancer patients with anxiety; ayahuasca and ibogaine as treatments for nicotine and opiate addiction; MDMA-assisted psychotherapy for PTSD; psychedelic neuroscience; and much more. A wide range of anthropological and social scientific research will include reports from the field (Earth and Fire Erowid), ethical considerations related to the medicinal use of psychedelics (Dr. Julie Holland), and a review of ayahuasca customs and uses (Dennis McKenna, Ph.D.). Plus: Nine full-day pre- and post- conference Workshops (April 18 & 21), a Holotropic Breathwork Workshop with Dr. Stanislav Grof (April 21-23), a Sunset Cruise (April 19), a Dinner & Performance (April 20), and the Marketplace & Moonlight Plaza (entire conference).
Don’t wait to make sure the world will still be spinning on December 22—register today!
See our Events Calendar for more!
10. The New York Times: A “Party Drug” May Help the Brain Cope With Trauma | view
12. VIDEO: CNN: Dr. Sanjay Gupta: Ecstasy as PTSD Treatment? | view
13. Military.com: PTSD Study Findings Reinforce Case for Ecstasy | view
14. Reuters: Researchers Say Form of Ecstasy May Heal Combat Trauma | view
15. Alternet: Research Points to Clear Benefits of MDMA for Post-Traumatic Stress Disorder | view
16. Stars and Stripes: Ecstasy Effective in Treatment of Lingering PTSD, New Study Finds | view
18. Reason: New Study Confirms MDMA’s Effectiveness in Psychotherapy | view
20. Care2: PTSD Sufferers See Long-Term Benefits From MDMA-Assisted Therapy | view
21. VIDEO: NBC San Diego: Scientists to Test Ecstasy for PTSD Vets | view
22. VIDEO: NBC Los Angeles: Party Drug May Help Tough Cases of PTSD | view
23. VIDEO: Rick Doblin Talks About the Future of Psychedelics | view
24. PODCAST: Brad Burge Talks about MDMA and PTSD on Being Bipolar Podcast | listen
Explore MAPS in the Media for even more psychedelic and medical marijuana research news.
Healing a Broken System: Veterans and the War on Drugs is a new report from the Drug Policy Alliance that examines the plight of returning veterans who struggle with incarceration and psychological wounds of war such as addiction and post-traumatic stress disorder‚Äîand suggests reforms that could improve the health and preserve the freedom of American soldiers returning from war zones and transitioning back to civilian life. This report recommends alternatives to incarceration for nonviolent drug offenses, increased access to overdose prevention programs and medication-assisted therapy, and research evaluating innovative treatment modalities such as medical marijuana and MDMA-assisted psychotherapy. View the issue brief.
The Ibogaine Experiences Research Group, a group of researchers not affiliated with MAPS, is interested in learning about your experience with ibogaine treatment. Researchers are conducting an online survey, which is completely anonymous, and invite anyone who has used ibogaine to participate. Researchers are based out of The School of Professional Psychology of Spalding University in Louisville, KY, USA. For more information, please click here.
Larry Hagman passed away on November 23, 2012, at the age 81. Larry was a famous Hollywood actor, known for his roles in Dallas and I Dream of Jeannie. He was a notable supporter of psychedelic research, as well as a generous contributor to MAPS. We thank Larry for his generosity, his support, his humor, and his friendship. Larry speaks with MAPS Founder Rick Doblin, The New York Times, and others about his personal experiences with psychedelics.